NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free XFOR Stock Alerts $0.94 +0.04 (+4.43%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$0.91▼$0.9850-Day Range$0.90▼$1.4752-Week Range$0.57▼$2.58Volume1.08 million shsAverage Volume2.56 million shsMarket Capitalization$158.40 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get X4 Pharmaceuticals alerts: Email Address X4 Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside218.1% Upside$3.00 Price TargetShort InterestHealthy7.27% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$116,003 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.34 out of 5 starsMedical Sector244th out of 931 stocksBiological Products, Except Diagnostic Industry33rd out of 154 stocks 3.3 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.27% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 7.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 2.9 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat Follows6 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,003.00 in company stock.Percentage Held by InsidersOnly 1.08% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here About X4 Pharmaceuticals Stock (NASDAQ:XFOR)X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Read More XFOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XFOR Stock News HeadlinesMay 13, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 9, 2024 | globenewswire.comX4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan FacilityMay 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical ProspectsMay 8, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comX4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 7, 2024 | seekingalpha.comX4 Pharmaceuticals GAAP EPS of -$0.26May 7, 2024 | investorplace.comXFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | sfgate.comX4 Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comX4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesMay 1, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for X4 Pharmaceuticals’ Xolremdi on Robust Clinical Efficacy and Favorable Market StrategyApril 30, 2024 | finance.yahoo.comXFOR: XOLREMDI™ Approved by FDA…April 30, 2024 | globenewswire.comX4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024April 29, 2024 | seekingalpha.comX4 Pharmaceuticals: FDA Approval For WHIM Warrants Further UpsideApril 29, 2024 | msn.comX4 gets FDA approval for Xolremdi for WHIM syndromeApril 29, 2024 | bizjournals.comX4 Pharmaceuticals’ bet on drug for ultra-rare disease pays off with FDA approvalApril 29, 2024 | marketwatch.comX4 Pharmaceuticals Gets FDA Approval for Xolremdi CapsulesApril 29, 2024 | finanznachrichten.deX4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM SyndromeApril 29, 2024 | markets.businessinsider.comX4 Pharma's XOLREMDI Capsules Gets FDA Approval To Treat WHIM SyndromeApril 29, 2024 | finance.yahoo.comUPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency diseaseApril 29, 2024 | reuters.comUS FDA approves X4 Pharmaceuticals' drug for immunodeficiency diseaseApril 29, 2024 | globenewswire.comX4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM SyndromeApril 18, 2024 | seekingalpha.comX4 Pharmaceuticals: PDUFA Excitement AheadApril 17, 2024 | msn.comX4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62April 11, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returnsSee More Headlines Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/28/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+218.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-275.36% Return on Assets-85.07% Debt Debt-to-Equity Ratio52.92 Current Ratio3.71 Quick Ratio3.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book3.04Miscellaneous Outstanding Shares167,940,000Free Float166,124,000Market Cap$158.40 million OptionableOptionable Beta0.51 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Paula Ragan Ph.D. (Age 54)CEO, President & Director Comp: $1.01MMr. Adam S. Mostafa (Age 44)CFO, Treasurer & Corporate Secretary Comp: $700.78kDr. Christophe Arbet-Engels M.B.A. (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $379.8kDr. Richard Peters M.D. (Age 61)Ph.D., Founder Dr. Renato T. Skerlj Ph.D.FounderDr. Keith T. Flaherty M.D. (Age 53)Founder & Member of Corporate Advisory Board Dr. Mary DiBiase Ph.D. (Age 63)Chief Operating Officer Comp: $661.59kDr. Arthur Taveras Ph.D. (Age 60)Chief Scientific Officer Dr. Robert David Arbeit (Age 76)Senior Vice President of Clinical Development and Translational Research Mr. Mark Baldry M.B.A. (Age 60)Chief Commercial Officer More ExecutivesKey CompetitorsNeon TherapeuticsNASDAQ:NTGNCidara TherapeuticsNASDAQ:CDTXApplied Genetic TechnologiesNASDAQ:AGTCHilleVaxNASDAQ:HLVXiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDBought 12,514 shares on 5/15/2024Ownership: 0.023%Vanguard Group Inc.Sold 181,138 shares on 5/10/2024Ownership: 4.661%SG Americas Securities LLCSold 26,846 shares on 5/7/2024Ownership: 0.012%GSA Capital Partners LLPSold 624,150 shares on 5/3/2024Ownership: 0.191%BNP Paribas Financial MarketsSold 221,969 shares on 5/1/2024Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions XFOR Stock Analysis - Frequently Asked Questions Should I buy or sell X4 Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks. What is X4 Pharmaceuticals' stock price target for 2024? 2 brokers have issued 1 year price targets for X4 Pharmaceuticals' stock. Their XFOR share price targets range from $1.00 to $5.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 218.1% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts. How have XFOR shares performed in 2024? X4 Pharmaceuticals' stock was trading at $0.8385 at the start of the year. Since then, XFOR shares have increased by 12.5% and is now trading at $0.9432. View the best growth stocks for 2024 here. When is X4 Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our XFOR earnings forecast. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.09. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.66%), GSA Capital Partners LLP (0.19%), BNP Paribas Financial Markets (0.04%), Price T Rowe Associates Inc. MD (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mark Baldry, Mary Dibiase, Michael S Wyzga, Murray Stewart and Paula Ragan. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XFOR) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
